This company has been marked as potentially delisted and may not be actively trading. NASDAQ:ATXS Astria Therapeutics (ATXS) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsEarningsFDA EventsHeadlinesInsider TradesOwnershipShort InterestTrendsBuy This Stock About Astria Therapeutics Stock (NASDAQ:ATXS) Get Astria Therapeutics alerts:Sign Up Key Stats Today's Range$12.45▼$12.5950-Day Range$12.44▼$13.2052-Week Range$3.69▼$13.29Volume3.20 million shsAverage Volume1.01 million shsMarket Capitalization$718.13 millionP/E RatioN/ADividend YieldN/APrice Target$24.50Consensus RatingHold Company Overview Astria Therapeutics, Inc. is a clinical‐stage biotechnology company dedicated to the development of innovative immunotherapies for oncology and autoimmune diseases. The company leverages proprietary cell engineering platforms to create next‐generation agents that engage T cells and natural killer (NK) cells, with the goal of directing potent and specific immune responses against tumor‐associated antigens or diseased tissues. Astria’s pipeline encompasses multiple therapeutic candidates across both hematologic and solid tumor indications, as well as autoimmune disorders. Its lead clinical programs are designed to harness bispecific constructs and cell‐based activation technologies to improve the precision and durability of immune killing, while additional preclinical assets focus on expanding the scope of treatable targets and refining safety profiles. Founded in 2018 and headquartered in San Diego, California, Astria Therapeutics collaborates with academic institutions, contract research organizations and regulatory authorities throughout North America and Europe to advance its product candidates. The company is guided by an executive team with extensive biopharmaceutical industry experience and a board of directors that brings together scientific, clinical and commercial expertise to support its strategic development plan.AI Generated. May Contain Errors. Read More Receive ATXS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Astria Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. ATXS Stock News HeadlinesAstria Therapeutics, Inc.: Stockholders Vote to Approve Acquisition by BioCryst Pharmaceuticals, Inc.January 22, 2026 | finanznachrichten.deAstria Stockholders Vote to Approve Acquisition by BioCrystJanuary 21, 2026 | finance.yahoo.comYour $29.97 book is free todayWhy Some Traders Skip Stocks Entirely You don't need a big account to trade options. In fact, options can give you up to 12 times the leverage of stocks — with a fraction of the capital tied up. This free guide lays it all out in plain English — from A to Z, with step-by-step examples you can follow in your own account.May 5 at 1:00 AM | Profits Run (Ad)Halper Sadeh LLC Encourages ATXS, GDOT, UBFO Shareholders to Contact the Firm to Discuss Their RightsDecember 20, 2025 | globenewswire.comAstria Therapeutics (ATXS) price target decreased by 17.94% to 21.62December 7, 2025 | msn.comAstria Therapeutics: Updating Target Price, BioCryst Deal Expected To Go Through, HoldNovember 30, 2025 | seekingalpha.comHalper Sadeh LLC Encourages ATXS, PCH, RYN Shareholders to Contact the Firm to Discuss Their RightsNovember 22, 2025 | globenewswire.comAnalysts Have Conflicting Sentiments on These Healthcare Companies: Codexis (CDXS), Milestone Pharmaceuticals (MIST) and Astria Therapeutics (ATXS)November 14, 2025 | theglobeandmail.comSee More Headlines ATXS Stock Analysis - Frequently Asked Questions How were Astria Therapeutics' earnings last quarter? Astria Therapeutics, Inc. (NASDAQ:ATXS) announced its earnings results on Wednesday, November, 12th. The biotechnology company reported ($0.55) earnings per share for the quarter, missing analysts' consensus estimates of ($0.41) by $0.14. The biotechnology company earned $0.71 million during the quarter, compared to analyst estimates of $10.67 million. When did Astria Therapeutics' stock split? Shares of Astria Therapeutics reverse split before market open on Friday, August 20th 2021.The 1-6 reverse split was announced on Friday, August 20th 2021. The number of shares owned by shareholders was adjusted after the market closes on Friday, August 20th 2021. An investor that had 100 shares of stock prior to the reverse split would have 17 shares after the split. When did Astria Therapeutics IPO? Astria Therapeutics (ATXS) raised $70 million in an IPO on Wednesday, June 24th 2015. The company issued 5,000,000 shares at $13.00-$15.00 per share. What other stocks do shareholders of Astria Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Astria Therapeutics investors own include CRISPR Therapeutics (CRSP), Voyager Therapeutics (VYGR), Waste Connections (WCN), American Water Works (AWK), DiamondRock Hospitality (DRH), The RMR Group (RMR) and AUO (AUOTY). Company Calendar Last Earnings11/12/2025Today5/05/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (11m+) 1-Year History May 25 Aug 25 Nov 25 Feb 26 May 26 ATXS's financial health is in the Green zone, according to TradeSmith. ATXS has been in this zone for over 11 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:ATXS CIK1454789 Webwww.catabasis.com Phone(617) 349-1971Fax617-273-2637Employees30Year Founded2008Price Target and Rating Average Price Target for Astria Therapeutics$24.50 High Price Target$49.00 Low Price Target$13.00 Potential Upside/Downside+94.8%Consensus RatingHold Rating Score (0-4)2.10 Research Coverage10 Analysts Profitability EPS (Trailing Twelve Months)($2.14) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$94.26 million Net MarginsN/A Pretax Margin-17,567.99% Return on Equity-68.81% Return on Assets-41.12% Debt Debt-to-Equity RatioN/A Current Ratio10.78 Quick Ratio10.78 Sales & Book Value Annual Sales$706 thousand Price / Sales1,017.18 Cash FlowN/A Price / Cash FlowN/A Book Value$3.97 per share Price / Book3.17Miscellaneous Outstanding Shares57,085,000Free Float54,516,000Market Cap$718.13 million OptionableOptionable Beta0.01 Social Links (Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.Get This Free Report This page (NASDAQ:ATXS) was last updated on 5/5/2026 by MarketBeat.com Staff. From Our PartnersSpaceX eyes a 1.75 trillion valuation - here's what to knowElon Musk's team has quietly filed confidential paperwork with the SEC for what Bloomberg estimates could be a...Brownstone Research | SponsoredIran's New Leader Just Said Something That Should Terrify Every AmericanIran's Supreme Leader has declared the Strait of Hormuz closed as leverage against the U.S. - and with 40% of ...American Alternative | SponsoredYour book attachedYour Download Link (Expiring) If you still haven't downloaded the free Simple Options Trading For Beginners...Profits Run | SponsoredMy feud with Zohran MamdaniEmmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...Stansberry Research | SponsoredSell 99% of Your Stocks, Do THIS Instead…Millionaire Trader Exposes: "The Single Stock Income Plan" With over 6,000 stocks on the market to choose ...The Oxford Club | SponsoredTrade this between 9:30 and 10:45 am ESTThe first 75 minutes of the trading day may be the most overlooked window for consistent opportunities.If you ...Base Camp Trading | SponsoredIran War Shock: What I Was Told In That Private MeetingYou’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially th...Banyan Hill Publishing | SponsoredElon Unveils AI Passive Income Stream for Millions of AmericansDuring Tesla's last earnings call, Elon Musk outlined a new AI-driven approach he says could generate $30,000-...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Astria Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Astria Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
